ClinicalTrials.gg
RecruitingNCT07469020CLE-PADUpdated Aug 12, 2026

CLE-PAD : Prevalence of PAD in Patients With Surgically Lumbar Spinal Stenosis

An interventional study of contrast-enhanced CT scan in PAD - Peripheral Arterial Disease, Lumbar Spinal Stenosis and Lower Limb Arterial Disease, sponsored by Rennes University Hospital. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Rennes University Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this interventional study is to evaluate the rate of existing lower limb peripheral artery disease (PAD) in patients with surgically lumbar spinal stenosis (LSS). PAD and LSS can present similar symptoms and it can be difficult to diagnose PAD using conventional methods, depending on the location of the arterial disease. The main questions it aims to answer are :

  • What's the prevalence of PAD in LSS patients?
  • Which exam among routine tools is the most accurate to diagnose PAD in this population? Around their surgery for LSS (a few weeks before or after), participants will be included in a vascular medicine service. After checking of eligibility criteria, they will undergo a contrast-enhanced CT scan for the diagnosis of PAD and various routine diagnostic tests: Doppler ultrasound, treadmill tests, pressure index, pulse palpation.
Read the detailed description

Lumbar spinal stenosis (LSS) is a debilitating degenerative condition in older people associated with lower back pain, pain in the lower limbs and a reduced quality of life. LSS can be treated surgically, but the results are mixed: 35% of patients report low satisfaction one year after surgery. The symptoms of LSC in the lower limbs can mimic those associated with peripheral arterial disease (PAD). The prevalence of PAD in the LSC population varies between 4.1% and 67.8% depending on the diagnostic tests used and the populations studied. Thus, the precise analysis of the prevalence of PAD and the sensitivity and specificity of PAD diagnostic tests in this population remain to be determined. These analyses would help to optimise PAD diagnostic tools, while possibly providing an explanation for the post-operative persistence of functional discomfort in CLE patients. Furthermore, a better understanding of the vascular system in the CLE population offers hope for optimising patient care, both from a medical and a medico-economic point of view.

The experimental visit takes place as soon as possible after receipt of the biological assessment and within a maximum period of 3 months. During this visit, specific research examinations will be performed, including stress tests (stress TcPO2 according to the modified Strandness protocol and stress TcPO2 according to the Gardner-Skinner increasing load protocol), as well as an injected scan of the aorta of the lower limbs. The pseudonymised CT scan will be sent to the sponsor for blind review. A follow-up telephone call will be made between 7 and 10 days after the CT scan to detect the occurrence of any adverse events. The study will then be completed for the participant.

02

Conditions studied

  • PAD - Peripheral Arterial Disease
  • Lumbar Spinal Stenosis
  • Lower Limb Arterial Disease

Browse trials for

03

In context

Spinal Stenosis

458 studies on the registry are indexed under Spinal Stenosis; 105 are open to participants now.

This study's planned enrollment of 49 is below the median of 80 across 281 interventional studies indexed under Spinal Stenosis.

Browse Spinal Stenosis studies →

Lead sponsor

Rennes University Hospital is the lead sponsor of 451 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presenting with a lumbar spinal stenosis with surgical indication, either unoperated or operated on less than 3 months ago
  • Affiliated with a social security scheme
  • Having received oral and written information about the protocol and having signed a written consent form to participate in this research.

Exclusion criteria

Exclusion Criteria:

  • emergency surgical care
  • to contrast enhanced CT scan

    • Stroke or myocardial infarction (MI) within the last 3 months
    • Known severe or poorly tolerated arrhythmia
    • Known severe or symptomatic left ventricular outflow obstruction
    • Decompensated heart failure
    • History within the last 3 months of venous thromboembolic disease, myopericarditis, endocarditis, aortic dissection or intracardiac thrombus
    • Severe uncontrolled hypertension (BP > 200/110 mmHg)
    • Inability to walk on the treadmill
    • Major lower limb amputation
    • Adult subject to legal protection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    Participants

    Diagnostic Test: contrast-enhanced CT scan

Interventions

  • Diagnostic testcontrast-enhanced CT scan

    contrast-enhanced CT scan

06

What researchers measure

Primary outcomes

  1. Number of patients with PAD identified during the contrast enhanced CT scan

    Number of patients with PAD identified during the contrast enhanced CT scan. PAD will be defined by the presence of at least one arterial stenosis ≥ 50% on the arterial axes located from the abdominal aorta to the origin of the tibiofibular arterial trunk, as determined by CT scan of the aorta and lower limbs in accordance with the recommendations.

    Time frame: 3 months

Secondary outcomes

  1. Efficiency of diagnosis test "pulse"

    determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "pulse" : the absence of distal pulses will be considered pathological

    Time frame: 3 months

  2. Efficiency of diagnosis test "systolic pressure index"

    determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "systolic pressure index" : A resting systolic pressure index ≤ 0.90 will be considered pathological in accordance with the recommendations.

    Time frame: 3 months

  3. Efficiency of diagnosis test "toe systolic pressure index"

    determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "toe systolic pressure index" : A resting toe systolic pressure index ≤ 0.70 will be considered pathological in accordance with the recommendations.

    Time frame: 3 months

  4. Efficiency of diagnosis test "Aorto-iliac and lower limb Doppler ultrasound"

    determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "Aorto-iliac and lower limb Doppler ultrasound " : velocimetric criteria for stenosis and Saint-Bonnet B and CD, E and 0 Doppler curves considered pathological (i.e. AOMI) in accordance with recommendations .

    Time frame: 3 months

  5. Efficiency of diagnosis test "exercise oxymetry"

    determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "exercise oxymetry " : Delta from rest oxygen pressure (DROP) ≤ -15 mmHg will be considered pathological (i.e. AOMI) in accordance with the recommendations. .

    Time frame: 3 months

07

Study locations

1 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2026, 0 months later.

Of 105 non-industry interventional studies with no phase under Spinal Stenosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 0 months is below that.

Counting every sponsor, half of 123 studies reached it within 30 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 13, 2026
StartEst.
Aug 2026
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07469020
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Aug 12, 2026

Study contacts

Marie-Laure Gervais
Contact
marie-laure.gervais@chu-rennes.fr
+33299284321
Marjolaine Talbot
study chair · Groupement des Hôpitaux de l'Institut Catholique de Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion